⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818680 | 0.81 | — | — | |
| SCHEMBL391705 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL16635284 | 0.79 | OXTR (0.32) | — | |
| SCHEMBL15749443 | 0.77 | — | — | |
| SCHEMBL28713899 | 0.77 | — | — | |
| SCHEMBL5048354 | 0.76 | RECQL (0.39) | — | |
| SCHEMBL10201421 | 0.75 | — | — | |
| SCHEMBL1425056 | 0.75 | — | — | |
| SCHEMBL16997464 | 0.75 | — | — | |
| SCHEMBL30014014 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024177362-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2024-08-29 | — | — | WO | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-110300755-B | Indanyl amino aza dihydro benzofuran acetic acid, pharmaceutical composition for treating diabetes | 勃林格殷格翰国际有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3580222-B1 | INDANYLAMINOAZADIHYDROBENZOFURANYLACETIC ACIDS, PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3580222-B1 | INDANYLAMINOAZADIHYDROBENZOFURANYLACETIC ACIDS, PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10550127-B1 | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-02-04 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-9493478-B2 | Fused ring compound containing furan or salt thereof and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| US-20150191478-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-07-09 | — | — | US | disclosed |
| EP-2876109-A1 | FUSED RING COMPOUND CONTAINING FURAN OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Yuhan Corporation (KR) | 2015-05-27 | — | — | EP | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |